Clinical Trials

Phase I Study of LOR-253 in Patients with Advanced or Metastatic Solid Tumors

Protocol
09-021
Full Title
Open-Label Phase I Study of LOR-253 HCL in Patients with Advanced or Metastatic Solid Tumors
Purpose

The purpose of this study is to find the highest dose of an investigational drug called LOR-253 that can be given safely in patients with advanced solid tumors that are not responding to standard therapies. LOR-253 works by inhibiting the concentration of zinc in cancer cells, leading to disruption of certain proteins and eventually to cancer cell death.

Investigator
Andrea Cercek, MD
Andrea Cercek - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of an advanced solid tumor that is not responding to standard therapy or for which no standard therapy exists.
  • At least 3 weeks must have passed since completion of prior therapies and entry into the study, and patients must have recovered from any serious side effects.
  • Patients with iron or copper overload syndromes (such as hemochromatosis or Wilson’s disease) may not participate.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Andrea Cercek at 646-888-4189.

Locations
ClinicalTrials.gov